Patents by Inventor William G. Bornmann
William G. Bornmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10363261Abstract: Provided herein are compounds of the formula (I) wherein the variables R1, R2, R3, R4, X1, X2, Y1, and A1 are as defined herein. Such compounds may be used, for example, for the inhibition of enolase enzymes, including preferential inhibition of one isoenzyme of over one or more of the other isoenzymes. Methods of treatment using these compounds, as well as pharmaceutical compositions thereof, are also provided.Type: GrantFiled: March 9, 2016Date of Patent: July 30, 2019Assignee: Board of Regents, The University of Texas SystemInventors: Florian Muller, David S. Maxwell, William G. Bornmann, Yu-Hsi Lin, Basvoju A. Bhanu Prasad, Zhenghong Peng, Duoli Sun, Nikunj Satani, M. Emilia Di Francesco, Ronald A. Depinho, Barbara Czako, Federica Pisaneschi
-
Patent number: 10208012Abstract: Compounds are provided that can exhibit anti-cancer and/or anti-inflammatory properties, in some aspects, methods of treating an inflammatory disease or a hyperproliferative disease, such as cancer, with the compounds are provided.Type: GrantFiled: March 13, 2014Date of Patent: February 19, 2019Assignee: Board of Regents, The University of Texas SystemInventors: Richard J. Ford, Jr., William G. Bornmann, Ashutosh Pal, Lan V. Pham, Zhenghong Peng, David Maxwell, Archito Tamayo
-
Publication number: 20180147219Abstract: Provided herein are compounds of the formula (I) wherein the variables R1, R2, R3, R4, X1, X2, Y1, and A1 are as defined herein. Such compounds may be used, for example, for the inhibition of enolase enzymes, including preferential inhibition of one isoenzyme of over one or more of the other isoenzymes. Methods of treatment using these compounds, as well as pharmaceutical compositions thereof, are also provided.Type: ApplicationFiled: March 9, 2016Publication date: May 31, 2018Inventors: Florian MULLER, David S. MAXWELL, William G. BORNMANN, Yu-Hsi LIN, Basvoju A. BHANU PRASAD, Zhenghong PENG, Duoli SUN, Nikunj SATANI, M. Emilia DI FRANCESCO, Ronald A. DEPINHO, Barbara CZAKO, Federica PISANESCHI
-
Publication number: 20160016931Abstract: Compounds are provided that can exhibit anti-cancer and/or anti-inflammatory properties, in some aspects, methods of treating an inflammatory disease or a hyperproliferative disease, such as cancer, with the compounds are provided.Type: ApplicationFiled: March 13, 2014Publication date: January 21, 2016Inventors: Richard J. FORD, Jr., William G. BORNMANN, Ashutosh PAL, Lan V. PHAM, Zhenghong PENG, David MAXWELL, Archito TAMAYO
-
Publication number: 20110312007Abstract: Provided are compositions and methods for intracellular detection of enzyme activity. One example of a composition is a histone deacetylase substrate comprising a compound of the following formula (I): One example of a method is a method for detecting histone deacetylase activity comprising introducing a compound according to formula (I) to a plurality of cells and monitoring the cells with magnetic resonance spectroscopy.Type: ApplicationFiled: August 1, 2011Publication date: December 22, 2011Inventors: Sabrina M. Ronen, Juri G. Gelovani, William G. Bornmann, Jihai Pang, Ashutosh Pal, William P. Tong, David S. Maxwell, Madhuri Sankaranarayanapillai
-
Publication number: 20100062465Abstract: Provided are compositions and methods for intracellular detection of enzyme activity. One example of a composition is a histone deacetylase substrate comprising a compound of the following formula (I): One example of a method is a method for detecting histone deacetylase activity comprising introducing a compound according to formula (1) to a plurality of cells and monitoring the cells with magnetic resonance spectroscopy.Type: ApplicationFiled: April 20, 2007Publication date: March 11, 2010Inventors: Sabrina M. Ronen, Juri G. Gelovani, William G. Bornmann, Jihai Pang, Ashutosh Pal, William P. Tong, Ashutosh Paz, William P. Tong, David S. Maxwell, Madhuri Sankaranarayanapillai
-
Patent number: 6887887Abstract: The present invention provides methods for the asymmetric synthesis of (S,S,R)-(?)-actinonin and its analogs and the compounds thereby synthesized having a structural formula: where R1 is an optionally substituted or halogenated alkyl, aryl, heteroalkyl or heteroaryl amine, said R1 further comprising a cyclic or bicyclic structure; R2 is methyl, CH2CH3, (CH2)2CH3, C(CH3)3, phenyl, 3,4-dichlorophenyl, biphenyl, benzyl, 4-hydroxybenzyl, piperidine, N-Boc-4-piperidine, CH2-(N-Boc-4-piperidine), 4-tetrahydropyran, CH2-4-tetrahydropyran, 3-methyl indolyl, 2-naphthyl, 3-pyridyl, 4-pyridyl, 3-thienyl; R3 is R2 or C3-8alkyl, R4 is C1-3alkyl; and R5 is NH2, OH, NHOH, NHOCH3, N(CH3)OH, N(CH3)OCH3, NHCH2CH3, NH(CH2CH3), NHCH2(2,4-(OCH3)2Ph, NHCH2(4-NO2)Ph, NHN(CH3)2, proline, or 2-hydroxymethyl pyrrolidine.Type: GrantFiled: June 25, 2003Date of Patent: May 3, 2005Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: William G. Bornmann, Francis Sirotnak, Howard Scher, Ephraim Vidal, Christopher Borella, David Scheinberg
-
Publication number: 20040259878Abstract: Provided herein is are novel fluorine-substituted methotrexates and methods of using magnetic resonance spectroscopy of these novel compounds to determine the sensitivity of or resistance of a tumor to methotrexate. Such methods may be used to predict the efficacy of methotrexate therapy or to devise alternate therapeutic strategies. Also provided are methods of treating tumors sensitive to methotrexate.Type: ApplicationFiled: February 12, 2004Publication date: December 23, 2004Inventors: Jason Koutcher, William G. Bornmann
-
Publication number: 20040019083Abstract: The present invention provides methods for the asymmetric synthesis of (S,S,R)-(−)-actinonin and its analogs and the compounds thereby synthesized having a structural formula: 1Type: ApplicationFiled: June 25, 2003Publication date: January 29, 2004Applicant: Sloan-Kettering Institute for Cancer ResearchInventors: William G. Bornmann, Francis Sirotnak, Howard Scher, Ephraim Vidal, Christopher Borelle, David Scheinberg
-
Patent number: 6660741Abstract: The present invention provides methods for the asymmetric synthesis of (S,S,R)-(−)-actinonin and its analogs and the compounds thereby synthesized having a structural formula: where R1 is an optionally substituted or halogenated alkyl, aryl, heteroalkyl or heteroaryl amine, said R1 further comprising a cyclic or bicyclic structure; R2 is methyl, CH2CH3, (CH2)2CH3, C(CH3)3, phenyl, 3,4-dichiorophenyl, biphenyl, benzyl, 4-hydroxybenzyl, piperidine, N-Boc-4-piperidine, CH2-(N-Boc-4-piperidine), 4-tetrahydropyran, CH2-4-tetrahydropyran, 3-methyl indolyl, 2-naphthyl, 3-pyridyl, 4-pyridyl, 3-thienyl; R3 is R2 or C3-8alkyl, R4 is C1-3alkyl; and R5 is NH2, OH, NHOH, NHOCH3, N(CH3)OH, N(CH3)OCH3, NHCH2CH3, NH(CH2CH3), NHCH2(2,4-(OCH3)2Ph, NHCH2(4-NO2)Ph, NHN(CH3)2, proline, or 2-hydroxymethyl pyrrolidine.Type: GrantFiled: March 19, 2002Date of Patent: December 9, 2003Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: William G. Bornmann, Francis Sirotnak, Howard Scher, Ephraim Vidal, Christopher Borella, David Scheinberg
-
Publication number: 20020198156Abstract: The present invention provides methods for the asymmetric synthesis of (S,S,R)-(−)-actinonin and its analogs and the compounds thereby synthesized having a structural formula: 1Type: ApplicationFiled: March 19, 2002Publication date: December 26, 2002Inventors: William G. Bornmann, Francis Sirotnak, Howard Scher, Ephraim Vidal, Christopher Borella, David Scheinberg
-
Patent number: 5541327Abstract: Substituted analogues of camptothecin possessing cytotoxic activity towards cancer cells, of the general structure: ##STR1## wherein E is H, CO.sub.2 R, CONH.sub.2, CONHR, CONR.sub.2, acyl, or CN; X is H, OH, or OR; R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are independently the same or different and are H, or a linear or branched chain alkyl, alkylaryl, or hydroxyalkyl group, or an aryl group; R.sup.5, R.sup.6, R.sup.7, R.sup.8, and R.sup.9 are independently the same or different and are H, or a linear or branched chain alkyl, alkylaryl, alkoxy, hydroxyalkyl, or aminoalkoxy group, or an aryl or aryloxy group, or a C-glycal, or CO.sub.2 R, nitro, cyano, Cl, F, Br, I, SR.sup.10, NR.sup.11 R.sup.12, OR.sup.13 ; R is H, or a linear or branched chain alkyl, alkylaryl, or hydroxyalkyl group, or an aryl group; R.sup.10, R.sup.11 and R.sup.12 are independently the same or different and are H, or a linear or branched chain alkyl, alkylaryl, hydroxyalkyl, or acyl group, or an aryl group; R.sup.Type: GrantFiled: November 14, 1994Date of Patent: July 30, 1996Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Samuel J. Danishefsky, William G. Bornmann, Wang Shen, Craig A. Coburn
-
Patent number: 5527924Abstract: The present invention provides two basic routes for the total synthesis of taxol having the structure: ##STR1## The present invention also provides the intermediates produced in the above processes, processes for synthesizing these intermediates as well as analogs to taxol. Both the intermediates and analogs to taxol may prove to be valuable anticancer agents.Type: GrantFiled: December 5, 1994Date of Patent: June 18, 1996Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Samuel J. Danishefsky, William G. Bornmann, Yves Queneau, Thomas V. Magee, Walter J. Krol
-
Patent number: 5488116Abstract: The present invention provides three basic routes for the total synthesis of taxol having the structure: ##STR1## The present invention also provides the intermediates produced in the above processes, processes for synthesizing these intermediates as well as analogues of taxol and nortaxol.Type: GrantFiled: November 2, 1993Date of Patent: January 30, 1996Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Samuel J. Danishefsky, William G. Bornmann, Yves Queneau, Thomas V. Magee, Walter J. Krol, John J. Masters, David K. Jung
-
Patent number: 5446047Abstract: Substituted analogues of camptothecin possessing cytotoxic activity towards cancer cells, of the general structure: ##STR1## wherein E is H, CO.sub.2 R, CONH.sub.2, CONHR, CONR.sub.2, acyl, or CN; X is H, OH, or OR; R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are independently the same or different and are H, linear or branched alkyl, linear or branched alkylaryl, hydroxyalkyl, or aryl; R.sup.5, R.sup.6, R.sup.7, R.sup.8, and R.sup.9 are independently the same or different and are H, linear or branched alkyl, linear or branched alkylaryl, aryl, CO.sub.2 R, alkoxy, aryloxy, hydroxyalkyl, C-glycal, nitro, cyano, aminoalkoxy, Cl, F, Br, I, SR.sup.10, NR.sup.11 R.sup.12, or OR.sup.13 ; R is H, alkyl, aryl, alkylaryl, hydroxyalkyl, or hydroxyalkyl; R.sup.10, R.sup.11 and R.sup.12 are independently the same or different and are H, alkyl, aryl, alkylaryl, hydroxyalkyl, or acyl; R.sup.13 is glycosyl; n is 0 or 1; with the proviso that when R.sup.1 is ethyl, and n is 0, E, R.sup.2, R.sup.3, and R.sup.4 are not all H.Type: GrantFiled: July 23, 1992Date of Patent: August 29, 1995Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Samuel J. Danishefsky, William G. Bornmann, Wang Shen
-
Patent number: 5416225Abstract: The present invention provides two basic routes for the total synthesis of taxol having the structure: ##STR1## The present invention also provides the intermediates produced in the above processes, processes for synthesizing these intermediates as well as analogs to taxol. Both the intermediates and analogs to taxol may prove to be valuable anticancer agents.Type: GrantFiled: March 30, 1992Date of Patent: May 16, 1995Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Samuel J. Danishefsky, William G. Bornmann, Yves Queneau, Thomas V. Magee, Walter J. Krol
-
Patent number: 5391745Abstract: Substituted analoguss of camptothecin possessing cytotoxic activity towards cancer cells, of the general structure: ##STR1## wherein E is H, CO.sub.2 R, CONH.sub.2, CONHR, CONR.sub.2, acyl, or CN; X is H OH, or OR; R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are independently the same or different and are H, or a linear or branched chain alkyl, alkylaryl, or hydroxyalkyl group, or an aryl group; R.sup.5, R.sup.6, R.sup.7, R.sup.8, and R.sup.9 are independently the same or different and are H, or a linear or branched chain alkyl, alkylaryl, alkoxy, hydroxyalkyl, or aminoalkoxy group, or an aryl or aryloxy group, or a C-glycal, or CO.sub.2 R, nitro, cyano, Cl, F, Br, I, SR.sup.10, NR.sup.11 R.sup.12, or OR.sup.13 ; R is H, or a linear or branched chain alkyl, alkylaryl, or hydroxyalkyl group, or an aryl group; R.sup.10, R.sup.11 and R.sup.12 are independently the same or different and are H, or a linear or branched chain alkyl, alkylaryl, hydroxyalkyl, or acyl group, or an aryl group; R.sup.Type: GrantFiled: January 11, 1993Date of Patent: February 21, 1995Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: Samuel J. Danishefsky, William G. Bornmann, Wang Shen, Craig A. Coburn